OncoMatch/Clinical Trials/NCT06854445
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Is NCT06854445 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies TQB2825 for diffuse large cell b-lymphoma.
Treatment: TQB2825 — The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive expression (positive)
Pathological diagnosis results containing CD20 positive expression
Required: MYC rearrangement negative (negative)
Myc rearrangement negative after anti-CD20 treatment must be provided
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Subjects with relapsed or refractory diffuse large B-cell lymphoma who have received at least 1 line of systemic therapy
Must have received: anti-CD20 therapy
Myc rearrangement negative after anti-CD20 treatment must be provided
Cannot have received: antibody drugs targeting CD3 and CD20 at the same time
previous use of other antibody drugs targeting CD3 and CD20 at the same time
Cannot have received: CAR-T cell therapy
Exception: within 3 months before the first dose
received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose
Cannot have received: immune cell therapy
Exception: within 3 months before the first dose
received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 3 months before the first dose
received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose
Cannot have received: R-GemOx
previous treatment with R-GemOx
Cannot have received: GemOx
previous treatment with ... GemOx
Cannot have received: chemotherapy
Exception: 4 times before the first dose, or still within 5 half-lives of the drug
received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment
Cannot have received: immunotherapy
Exception: 4 times before the first dose, or still within 5 half-lives of the drug
received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment
Cannot have received: monoclonal antibody therapy
Exception: 4 times before the first dose, or still within 5 half-lives of the drug
received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment
Cannot have received: radiotherapy
Exception: 2 times before the first dose
2 times received radiotherapy or small molecule targeted drugs
Cannot have received: small molecule targeted drugs
Exception: 2 times before the first dose
2 times received radiotherapy or small molecule targeted drugs
Cannot have received: Chinese patent medicines with clear anti-tumor indications
Exception: 2 times before the first dose
received treatment with Chinese patent medicines with clear anti-tumor indications in the package insert of National Medical Products Administration (NMPA)-approved drugs 2 times before the first dose
Lab requirements
Blood counts
Laboratory tests meet specific criteria; failure to recover from adverse reactions to CTCAEv5.0 criteria ≤ grade 1 from previous treatment excluded
Kidney function
Renal failure requiring hemodialysis or peritoneal dialysis, previous history of nephrotic syndrome excluded
Liver function
Laboratory tests meet specific criteria; decompensated cirrhosis (Child-Pugh class B or C liver function) and active hepatitis excluded
Cardiac function
Have major cardiovascular disease excluded
Laboratory tests meet specific criteria; decompensated cirrhosis (Child-Pugh class B or C liver function) and active hepatitis excluded; Renal failure requiring hemodialysis or peritoneal dialysis, previous history of nephrotic syndrome excluded; Have major cardiovascular disease excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06854445 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody drugs targeting CD3 and CD20 at the same time, CAR-T cell therapy, immune cell therapy disqualifies patients from enrollment.
Does this trial require CD20?
Yes, CD20 positive expression is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC rearrangement negative is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify